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Abstract
Purpose—HIV prevalence estimates among transgender women in the United States are high, 
particularly among racial/ethnic minorities. Despite increased HIV risk and evidence of racial 
disparities in HIV prevalence among transgender women, few data are available to inform HIV 
prevention efforts.
Methods—A transgender HIV-related behavioral survey conducted in 2009 in 3 US metropolitan 
areas (Chicago, Houston, and Los Angeles County), used respondent-driven sampling to recruit 
227 black (n = 139) and Latina (n = 88) transgender women. We present descriptive statistics on 
sociodemographic, health care, and HIV-risk behaviors.
Results—Of 227 transgender women enrolled, most were economically and socially 
disadvantaged: 73% had an annual income of less than $15,000; 62% lacked health insurance; 
61% were unemployed; and 46% reported being homeless in the past 12 months. Most (80%) had 
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visited a health care provider and over half (58%) had tested for HIV in the past 12 months. 
Twenty-nine percent of those who reported having an HIV test in the past 24 months self-reported 
being HIV positive. Most of the sample reported hormone use (67%) in the past 12 months and 
most hormone use was under clinical supervision (70%). Forty-nine percent reported condomless 
anal sex in the past 12 months and 16% reported ever injecting drugs.
Conclusion—These findings reveal the socioeconomic challenges and behavioral risks often 
associated with high HIV risk reported by black and Latina transgender women. Despite low 
health insurance coverage, the results suggest opportunities to engage transgender women in HIV 
prevention and care given their high reported frequency of accessing health care providers.
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INTRODUCTION
In the United States, approximately 0.6% of the population, or 1.4 million individuals, 
identify as trans-gender.1 Transgender women are at high risk for HIV infection. A meta-
analysis of studies conducted among transgender women in 5 high-income countries 
(including the United States) estimated a pooled HIV prevalence of 22%.2 In addition, an 
earlier systematic review from studies in the United States showed that the highest estimates 
of HIV prevalence were among black transgender women.3
Similar to other populations at risk for HIV, transgender women engage in risk behaviors 
such as condomless anal intercourse4,5 and needle sharing when injecting illicit drugs.5,6 
However, for transgender women these behaviors occur within a context of stigma and 
discrimination exceeding that experienced by other populations at elevated risk, including 
men who have sex with men. The National Transgender Discrimination Survey conducted in 
2008 found that 90% of transgender respondents had experienced harassment, mistreatment, 
or discrimination on the job, which impacted their quality of life and ability to sustain 
themselves financially and emotionally.7 Challenged by discrimination in the formal 
workplace, some transgender women are forced to work in the underground economy by 
engaging in sex work or selling drugs.7–9 In addition, black and Latina transgender women 
compose most transgender sex workers in the United States and are more likely than white 
transgender women to engage in unprotected sex and nonhormonal injection drug use, and, 
therefore, are more susceptible to HIV infection and sexually transmitted infections 
(STIs).10 Additional challenges reported by transgender women include psychological and 
physical abuse and violence,4 unemployment and unstable housing,11,12 lack of social 
support,13 low self-esteem and experienced transphobia,14 and substance abuse.12,15,16 
Many transgender women also experience an unmet need for social interactions that affirm 
their gender identity.17
Transgender women may undertake a range of medical steps to actualize and maintain their 
true gender identity. Medical treatments may include ongoing hormone therapy and 
feminization procedures to mitigate masculine features, and for those who are compelled to 
and elect it, gender affirming surgical procedures.18–20 However, regardless of the stage of 
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transition, all transgender women need access to quality affordable health care, preferably 
from providers experienced in transgender health.21 Unfortunately, few transgender women 
have access to low-cost care and safe, inclusive medical environments.22,23 In fact, many 
trans-gender women face stigma, discrimination, and harassment within the health care 
system that act as barriers to obtaining quality care.7 Evidence shows that the current 
medical workforce lacks appropriate training in transition-related needs of transgender 
persons, their broader health issues, and general transgender-community competency (eg, 
being sensitive about pronouns and names used, gender assessment on forms, etc.).22 Not 
only do these barriers present challenges to providing general health care, they also 
undermine HIV prevention and treatment in the clinical setting as transgender persons may 
not want to discuss their HIV status or reveal risk behaviors.22,24–28 Improving access to 
quality, affordable transgender-sensitive health care services could be beneficial in 
preventing HIV infection among transgender women. This is especially warranted given the 
HIV disparities among transgender women of color.
We used behavioral data from a pilot of the Trans-gender HIV Behavioral Survey (THBS), 
which was conducted to determine the feasibility of recruiting transgender women living in 
3 metropolitan areas using respondent-driven sampling (RDS)29–32 and to evaluate a 
transgender-specific questionnaire. The behavioral data were collected anonymously to 
describe: (1) sociodemographic characteristics, (2) hormone use and other health care 
utilization, and (3) behavioral variables related to acquiring and transmitting HIV infection 
among a sample of transgender women. The questionnaire was adapted from an instrument 
used in the National HIV Behavioral Surveillance system. Input on the questionnaire was 
provided by a panel of transgender subject-matter experts and transgender-specific items 
were cognitively tested among transgender persons before piloting the survey in the 
community. These data can be used to understand health care utilization and HIV prevention 
and treatment efforts with transgender women of color and serve as a means to measure 
progress in those efforts.
METHODS
In this study, we defined transgender as someone whose gender identity differs from the one 
they were assigned at birth. We recruited black and Latina transgender women into the 
survey using RDS in 3 metropolitan areas: Chicago, IL; Houston, TX; and Los Angeles 
County, CA. RDS has been effective at recruiting hard-to-reach populations33 including 
transgender persons.34,35 Each metropolitan area identified a sample of transgender women 
starting with a small number of initial recruits or seeds. The initial seeds were black or 
Latina transgender women identified by survey staff through outreach in the local 
transgender community or by referral from a local organization serving the transgender 
community. Each seed completed the interview and was asked to recruit up to 5 black or 
Latina transgender women from their peer networks. These subsequent recruits, if eligible, 
also completed the interview and were offered the opportunity to recruit up to 5 of their 
peers. Peer recruitment continued for either 3 months or until the sample size targets of 100 
transgender women participants per metropolitan area was reached. Respondents received 
$20–$25 for the interview and an additional $10 for each referred peer who was eligible and 
participated in the survey. To be eligible to participate in the survey, individuals had to be: 
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(1) black or Latina; (2) assigned male at birth based on self-report, and currently identify as 
female or transgender; (3) 15 years of age or older; (4) a current resident of the participating 
metropolitan area; and (5) able to complete a computer-assisted questionnaire in English. 
The study staff administered a computerized eligibility screener among those who were 
referred to the study. If the respondent was eligible, the study staff reviewed the consent 
form with the respondent and obtained oral consent for participation. The study received a 
waiver of parental permission for participants aged 15 to 17 and collected oral assent from 
the youth for participation. After consenting or assenting to the interview, the study staff 
conducted a short tutorial on how to complete an audio computer-assisted self-administered 
interview (ACASI) using headsets and a laptop computer. The ACASI questionnaire was 
conducted using a headset and assessed sociodemographic characteristics, health care 
utilization variables, HIV-associated risk behaviors, and HIV prevention experiences. 
Participants completed the computerized questionnaire in approximately 45 minutes at 
established locations, where the interview could be conducted in private. The protocol was 
approved by local institutional review boards in each of the 3 participating metropolitan 
areas and the Centers for Disease Control and Prevention’s institutional review board.
Data Analysis
We present descriptive findings for key indicators including: (1) sociodemographic 
characteristics (eg, annual income, health insurance, employment, homelessness, and 
incarceration); (2) HIV and STI prevention activities (eg, HIV testing/treatment and STI 
screening) and health care use (eg, recent visit to a health care provider); (3) hormone and 
other transgender health care use (eg, hormone/silicone use, clinician-supervised hormone 
replacement therapy, and gender affirming surgical procedures); and (4) HIV sexual and 
drug risk behaviors (eg, sexual risk behaviors, exchange sex, and alcohol/substance use). We 
combined interview data from all 3 THBS sites and because of the small sample from each 
site did not adjust the analysis to account for RDS sampling.
Sociodemographic Characteristics and HIV/STI Prevention Activities
The data for participant characteristics were analyzed according to gender identity, race/
ethnicity, age group, education level, employment status, health insurance status, annual 
household income, recent homelessness, recent arrest, HIV/STI status and testing measures, 
HIV treatment status, recent health care provider visits, recent receipt of free condoms, and 
metropolitan statistical area. Responses for gender identity were categorized as either female 
or trans-gender. Responses for race/ethnicity were categorized into mutually exclusive 
categories: non-Hispanic black and Latina. Transgender women of Latina ethnicity could 
report being of any race. Additional analyses were conducted to stratify the sample of black 
and Latina transgender women by race/ethnicity to test whether there were meaningful 
differences between the 2 groups. Education level was categorized as less than high school, 
high school diploma or equivalent (eg, general educational development diploma), and some 
college/technical degree or higher. Employment status was categorized as employed full-
time, part-time, unemployed/disabled, or other. Health insurance was categorized as none, 
private only (eg, health insurance obtained through a private insurance policy or employer, 
TRICARE, CHAMPUS, or membership in a health maintenance organization), public only 
(eg, Medicare, Medicaid, or Veterans Administration coverage), or other coverage. Annual 
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household income was collected from participants in ranges, which were collapsed into 4 
categories based on the income distribution of respondents: <$10,000, $10,000–$14,999, 
$15,000–$19,999, and ≥$20,000. Income was not adjusted for household size because most 
of the participants had a household size of one. HIV status was asked in a series of questions 
as “Have you ever been tested for HIV?,” “In the past 2 years, how many times have you 
been tested for HIV?,” “That time you got tested for HIV in the past 2 years, did you get the 
result of the test?” and “What was the result of your most recent HIV test?” Hepatitis C 
infection was asked as “Has a doctor, nurse or other health care provider ever told you that 
you had hepatitis?” and “What type or types of hepatitis have you had?” Syphilis infection 
was assessed as “In the past 12 months, has a doctor, nurse, or other health care provider 
told you that you had syphilis?” and “Even though a health care provider didn’t tell you that 
you had syphilis, did you have a test to check for syphilis in the past 12 months?” In 
addition, 3 time frames for self-reported behaviors or experiences were included in analyses: 
ever (ie, at any point in the participant’s lifetime), during the 12 months before the interview, 
and the most recent time the participant engaged in the behavior.
Hormone and Other Transgender Health Care Use
Transgender health care was measured by hormone therapy use (never, in the past 12 
months, or not within the past 12 months), injection of hormones (ever and in the past 12 
months), insurance coverage and clinical supervision of hormone therapy, injection of 
silicone or other substance for feminization, and sexual reassignment surgery (ever and 
whether covered by insurance, if insured). Transgender women who reported injecting their 
hormones were asked for the source of the needles used for injection. Participants were also 
asked if they disclosed their transgender identity to their health care providers.
HIV Sexual and Drug Risk Behaviors
HIV risk was measured by sexual behavior and drug and alcohol use. Sexual behavior was 
measured by assessing the cumulative number of male sex partners, anal sex, condomless 
anal sex, exchange sex for money or drugs, and forced sex with male partners in the past 12 
months. Details about anal sex with male partners are presented as key risk behaviors for 
HIV transmission. Male sex partners were categorized as main or casual partners. A main 
partner was someone with whom the participant felt most committed (eg, boyfriend, spouse, 
significant other, or life partner). A casual partner was someone with whom the participant 
did not feel committed, whom she did not know very well, or with whom she had sex in 
exchange for something such as money or drugs. Participants could report having more than 
one main or casual partner in the past 12 months. We also assessed whether transgender 
women had sex with cisgender female partners in the past 12 months.
For alcohol and substance use, participants were asked about their use during the past 12 
months of multiple types of drugs (injection or noninjection) that had not been prescribed 
for them. Alcohol use was defined as drinking any alcohol such as beer, wine, malt liquor, or 
hard liquor. Binge drinking is reported and was defined as drinking more than 5 alcoholic 
beverages at one sitting in the 30 days before the interview. Participants were also asked 
whether they had sex with their last male partner while under the influence of drugs and/or 
alcohol.
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RESULTS
During February to April 2009, we used RDS to recruit a total of 241 transgender women, of 
which 37 were seeds. Of the 241 individuals screened for eligibility, 232 were assigned a 
male sex at birth; 231 identified as female, transgender, or a gender identity other than male, 
and 229 met the eligibility criteria. Two records with incomplete questionnaire data were 
excluded from the analysis. Our analysis includes data from 227 questionnaires completed 
across 3 participating sites: Chicago, IL (n = 67); Houston, TX (n = 59); and Los Angeles 
County, CA (n = 101).
Sociodemographic Characteristics
Of the 227 respondents, 61% were black and 39% were Latina. A majority of the Latina 
respondents were from Los Angeles County, CA. Most (64%) of the respondents were 30 
years of age or older, one-third (34%) had not completed high school, and nearly two-thirds 
(61%) were unemployed at the time of the interview (Table 1). Most (73%) respondents had 
an annual income less than $15,000, 46% reported being homeless in the past 12 months, 
and 24% reported being arrested in the past 12 months. Most (62%) of the respondents did 
not have health insurance.
HIV and STI Prevention Activities
Despite a majority not having health insurance, most (80%) had visited a health care 
provider in the past 12 months. Because of survey administration errors, only participants 
reporting an HIV test in the 2 years before interview (n = 152) were asked about their HIV 
status. Of these women, 29% reported being HIV positive. Among all participants, 58%, 
40%, and 47% had tested for HIV, hepatitis C virus, and syphilis in the past year, 
respectively. Twelve percent reported being hepatitis C virus–positive, and 7% reported a 
syphilis diagnosis in the past 12 months (Table 1).
Of those who had not been tested for HIV in the past 12 months, the most common reason 
for not having an HIV test was that the participant thought she was at low risk for HIV 
infection (20%), followed by fear of testing positive (11%). Structural barriers to HIV 
testing (eg, lack of transportation, money, or health insurance) were reported as the main 
reason for not testing by only a few participants (ie, ≤3 persons reporting each). Of those 
who reported being HIV positive, 75% were on antiretroviral therapy (data not shown).
Hormone Use and Other Transgender-Specific Health care
Hormone use was common among participants: 83% had ever taken hormones and 62% had 
ever injected hormones. In addition, 67% had taken hormones and half had injected 
hormones in the past 12 months. Among the 38% of participants with health insurance, 66% 
reported their insurance covered hormone therapy. Most of the transgender women using 
hormones reported using hormones under clinical supervision (70%) and 66% had obtained 
the needles for hormone injections from a doctor. Only 6% had injected silicone or any other 
substance for physical feminization in the past 12 months. A small number (4%) reported 
having undergone vaginal construction or sex reassignment surgery and only 5% of 
transgender women with health insurance reported their insurance covered sex reassignment 
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surgery. Of the 181 participants who had seen a health care provider in the past 12 months, 
88% reported that they disclosed their transgender identity to their health care provider 
(Table 2).
HIV Sexual and Drug Injection Risk
Table 3 shows HIV-risk behaviors that occurred in the 12 months before interview as 
reported by study participants. Forty-eight percent reported having 5 or more male sex 
partners, whereas only 7% reported having sex with a female in the past 12 months. 
Seventy-eight percent reported anal sex with male partners and 49% reported condomless 
anal sex with male partners. Exchange of sex for money or drugs was reported by 42% of 
the sample. Sixteen percent also reported being forced to have sex with another person in the 
past 12 months.
Illicit noninjection drug use in the past 12 months was common (38%). Of those reporting 
illicit drug use, marijuana was most common (81%) followed by ecstasy (30%), crack 
cocaine (29%), powdered cocaine (28%), and crystal meth-amphetamine (24%). Although 
16% of the transgender women reported injecting illicit drugs in their lifetime, only a small 
proportion (4%) had done so in the past 12 months. In addition, most (65%) transgender 
women had consumed an alcoholic beverage in the past 30 days and 35% reported binge 
drinking in the past 30 days. Thirty-seven percent reported sex under the influence of drugs 
and/or alcohol with their most recent male sex partner.
DISCUSSION
Findings from this THBS pilot confirm and further reveal the myriad socioeconomic 
disadvantages faced by black and Latina transgender women. Although it is not known to 
what extent the sample under sampled transgender women is of high socioeconomic status, 
the transgender women in this sample faced economic challenges, such as annual incomes 
below the federal poverty level, unemployment, or homelessness. A large proportion of 
black and Latina transgender women in the sample reported high-risk sexual behaviors such 
as exchange sex, multiple sex partners, and condomless anal intercourse. In addition, 29% of 
the transgender women in the survey who provided their recent HIV test result were HIV 
positive.
Findings from this study are consistent with other studies reporting low income35 and high 
prevalence of homelessness5 among transgender women. These outcomes may stem from 
harassment and discrimination, which impacts educational attainment and future success in 
obtaining jobs and/or housing.7 Some strides have been made in improving the laws and 
policies banning discrimination of transgender persons in the workplace and protecting 
transgender tenants or home buyers.36 However, although policies are changing or are being 
enacted, to date it is likely that they neither cover all transgender women living in the United 
States, nor do they include every setting. Transgender women could still benefit from 
programs to increase opportunities for employment training, housing, and other basic needs.
Despite the many socioeconomic disadvantages and elevated health risks faced by this 
sample of black and Latina transgender women, including 62% who lacked health care 
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coverage, many participants visited a health care provider or were tested for HIV in the year 
before the interview. Also, of those taking hormones, most had clinically supervised 
hormone therapy and most of the transgender women who had administered their own 
injections had received their syringes from their doctor or a pharmacy. These findings show 
relatively recent interactions with the health care system and opportunities to link these 
women to HIV prevention, treatment, and care services.
However, many transgender women still lack quality, affordable transgender-sensitive health 
care in general.20 Most likely need clinical guidance to assist with their gender transition 
and maintenance, which may include the use of hormones and physical feminization 
procedures. Clinical supervision of hormone replacement therapy is important because 
unsupervised hormone therapy may put patients at risk of excessive or inadequate dosing, 
which could lead to side effects or risks of blood clots. Some evidence has linked hormone 
therapy with cardiovascular disease, whereas these studies did not control for risk factors 
such as tobacco use.19 About 30% of the transgender women who used hormones in this 
survey reported that they did so unsupervised. In addition, physical feminization procedures, 
like black-market injections of silicone or other substances, are dangerous and life 
threatening, although these procedures were rare in the sample.37
Given the reported recent interactions with the health care system, integrating HIV 
prevention into the primary care of transgender women could be beneficial in improving 
antiretroviral adherence to treat (antiretroviral therapy) or prevent (pre-exposure 
prophylaxis) HIV infection as research has shown that transgender women may have 
difficulty integrating their antiretroviral medicines into their daily routine38–40 and some 
may be reluctant to take antiretroviral medications because of a belief that there are negative 
interactions with their hormones.28 However, these data showed that a large percentage 
(75%) of the self-reported HIV-positive transgender women were on antiretroviral therapy 
and almost all had disclosed their gender identity to a health care provider. Nevertheless, 
health care providers could serve an important role in monitoring the biological risks 
associated with hormone therapy, educating their patients about the importance of taking 
antiretroviral therapy (treatment or prevention), and discussing drug interactions (or lack 
thereof) between antiretroviral medications and hormones.28,41–43 In addition, being under a 
physician’s care has been reported to be associated with reducing HIV-risk behaviors and 
obtaining clean needles for hormone injections.41 Future behavioral surveys should assess 
the factors affecting adherence to antiretroviral medicines.
Having access to health care does not necessarily mean it is affordable. Despite the health 
care needs and frequency of health care visits reported by transgender women, we reported 
that nearly 62% of the transgender women were without insurance, which is over 3 times as 
high as the general public in the United States in 2009 (ie, 17%).35 Since 2009, opportunities 
to obtain insurance coverage were made available through the Patient Protection and 
Affordable Care Act (ACA) of 2010.42 However, despite the introduction of the ACA (after 
these data were collected), more efforts are likely needed to increase access to health 
services in this population. Although the ACA prohibits insurance companies from denying 
coverage due to pre-existing conditions, it does not require companies to cover sex 
reassignment surgeries or other transition-related procedures.36 In our study, only 5% of the 
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transgender women sampled who reported having insurance also reported that their coverage 
included gender affirming surgeries.
This study has several limitations. The data may not represent all black and Latina 
transgender women living in the 3 participating sites and should not be generalized. These 
data are also acquired from a convenience sample and the data have not been weighted to 
account for biases because of the sampling strategy. It is likely transgender women of high 
socioeconomic status are underrepresented in this sample. Also because the interview was 
not translated into Spanish, only Latina transgender women who were fluent in English 
could take part in the survey. Studies from the broader Latino community suggest that 
monolingual, Spanish-speaking trans-gender women may be more socioeconomically 
challenged and likely to be uninsured compared with bilingual Latina transgender 
women43,44 In addition, because 2 of the 3 sites did not meet the sample size goal of 100, 
almost half of the sample is composed of transgender women from Los Angeles County. 
Last, this study likely underestimates HIV prevalence. We did not conduct HIV testing as 
part of study enrollment and only relied on self-report of HIV status. In addition, the 
program for the ACASI had an error that inadvertently allowed 20% of the participants to 
skip the question asking the most recent HIV test result if they did not report an HIV test in 
the past 2 years, thus the true prevalence of HIV in this sample is unknown. The percentage 
self-reporting as HIV positive in the survey could underestimate the true positivity in the 
sample if longstanding HIV-positive transgender women were more likely than uninfected 
women to not have an HIV test in the 2 years before the interview. Therefore, it is not known 
how well the self-reported HIV status rates in this study compare with overall population 
prevalence for trans-gender women of color. It is also important to note that these data show 
that regular HIV testing was low and did not meet CDC recommendations for HIV testing 
for populations at higher risk in place at the time of the survey, for example, HIV testing 
every 3–6 months may be advised for sexually active men who have sex with men.45
CONCLUSION
The updated National HIV/AIDS Strategy for the United States released in July 2015, 
addresses the urgent need to reduce new HIV infections among transgender women while 
also noting the high burden of HIV among black transgender women.46 Transgender women 
in the United States face many socioeconomic challenges, including lack of health 
insurance. Unlike other populations at risk for HIV, many transgender women will seek 
medical assistance with their gender transition, and therefore, need to routinely visit a health 
care provider who is knowledgeable of transgender health issues.20 Supportive interactions 
with the health care system could provide useful opportunities for HIV prevention, by 
providing HIV testing, risk-reduction options, such as pre-exposure prophylaxis for eligible 
HIV-negative trans-gender women, and antiretroviral treatment for those who are HIV 
positive. Finally, these findings suggest that more information about the interactions 
transgender women have with the health care system is needed. Subsequent behavioral 
surveys among transgender women should monitor improvements to health care access, 
utilization and quality as well as for assessing the socioeconomic indicators in this 
population.
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TABLE 1
Characteristics of Participants, Transgender HIV Behavioral Survey, 3 US Cities, 2009
Characteristics
Total
No. %
Gender
 Female 50 22.0
 Transgender 177 78.0
Race/ethnicity
 Black 139 61.2
 Latina 88 38.8
Age at interview, yrs
 15–17 2 0.9
 18–24 47 20.7
 25–29 33 14.5
 30–39 66 29.1
 40+ 79 34.8
Education
 Less than high school 78 34.4
 High school graduate 83 36.6
 Some college or higher 66 29.1
Employment status
 Employed full-time 34 15.0
 Employed part-time 26 11.5
 Unemployed/disabled for work 138 60.8
 Other 29 12.8
Health insurance
 None 140 61.7
 Public 14 6.2
 Private 57 25.1
 Other 15 6.6
Household income
 less than $10,000 132 58.1
 $10,000–$14,999 33 14.5
 $15,000–$19,999 20 8.8
 $20,000 or more 32 14.1
Homeless in past 12 mo
 No 121 53.3
 Yes 105 46.3
Arrested in past 12 mo
 No 171 75.3
 Yes 54 23.8
Self-reported HIV status*
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Characteristics
Total
No. %
 Negative 108 71.1
 Positive 44 28.9
Self-reported hepatitis C status
 Negative 197 86.8
 Positive 28 12.3
Diagnosed with syphilis in past 12 mo
 No 208 92.9
 Yes 16 7.1
Visited health care provider
 No 44 19.6
 Yes 181 80.4
HIV testing in past 12 mo
 No 89 42.0
 Yes 123 58.0
Hepatitis C testing in past 12 mo
 No 134 59.6
 Yes 91 40.4
Syphilis testing in past 12 mo
 No 119 53.1
 Yes 105 46.9
Received free condoms in past 12 mo
 No 46 20.3
 Yes 180 79.3
Currently receiving antiretroviral treatment†
 No 11 25.0
 Yes 33 75.0
Metropolitan Statistical Area
 Chicago 67 29.5
 Houston 59 26.0
 Los Angeles 101 44.5
Total 227
May not sum to total due to rounding and missing values.
*Among 152 transgender persons tested in the past 2 years and who knew their recent test result.
†Of 44 participants who self-reported being infected with HIV.
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TABLE 2
Hormone and Other Transgender Health Care Utilization, Transgender HIV Behavioral Survey, 3 US Cities, 
2009
Behaviors
Total
No. %
Hormone use
 Never 38 16.7
 Used but not in the past 12 mo 36 15.9
 Used in the past 12 mo 153 67.4
Ever injected hormones
 No 87 38.3
 Yes 140 61.7
Injected hormones in past 12 mo
 No 109 48.0
 Yes 113 49.8
Hormone therapy covered by health insurance*
 Coverage does not include hormone therapy 26 30.2
 Coverage includes hormone therapy 57 66.3
 Do not know if coverage includes hormone therapy 3 3.5
Clinical supervision of hormone therapy†
 No 46 30.3
 Yes 106 69.7
Type of provider of hormone needles‡
 Prescription from the doctor 74 65.5
 Internet 2 1.8
 Someone on the street 21 18.6
 A friend 34 30.1
 Other 8 7.1
Ever injected silicone or similar substance
 No 169 74.4
 Yes 58 25.6
Injected silicone or similar substance in past 12 mo
 No 208 91.6
 Yes 14 6.2
Had vaginal construction or sex reassignment surgery
 No 218 96.5
 Yes 8 3.5
SRS covered by health insurance*
 Coverage does not include SRS 70 81.4
 Coverage includes SRS 4 4.7
 Do not know if coverage includes SRS 12 14
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Behaviors
Total
No. %
Out about transgender identity to health care provider§
 Not out to health care provider 20 11.8
 Out to health care provider 150 88.2
Total 227
May not sum to total due to rounding and missing values.
*Of the 86 transwomen who had health coverage.
†Of the 153 participants who used hormones in the 12 months preceding the interview.
‡Of the 113 participants who injected hormones in the 12 months preceding the interview; participants may have used more than one source.
§Of the 170 transwomen who reported having and seeing a health care provider in the past 12 mo.
SRS, sex reassignment surgery.
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TABLE 3
Sexual Behaviors and Substance Use, Transgender HIV Behavioral Survey, 3 US Cities, 2009
Past 12 Mo Sexual Behaviors
Total
No. %
Number of male sex partners
 None 29 13.4
 1 33 15.2
 2–4 51 23.5
 5–10 44 20.3
 11+ 60 27.7
Anal sex with male partners
 No 47 22.2
 Yes 165 77.8
Condomless anal sex with male partners
 No 109 51.4
 Yes 103 48.6
Exchanged money or drugs for sex with a male casual partner
 No 123 57.7
 Yes 90 42.3
Forced to have sex with a male partner in past 12 mo
 No 180 84.5
 Yes 33 15.5
Alcohol and Substance Use
Alcohol consumed in past 30 d
 No 77 34.7
 Yes 145 65.3
Binge drinking in past 30 d
 No 143 64.7
 Yes 78 35.3
Used noninjection drugs in past 12 mo
 No 140 62.0
 Yes 86 38.0
Type of noninjection drugs used in the preceding 12 mo*
 Marijuana 70 81.4
 Ecstasy 26 30.2
 Crack cocaine 25 29.1
 Powdered cocaine 24 27.9
 Crystal meth (tina, crank, ice) 21 24.4
 Downers (Valium, Ativan, Xanax) 13 15.1
 Painkillers (OxyContin, Bicodin, Percocet) 11 12.8
 Poppers 10 11.6
 Hallucinogens (LSD, mushrooms), heroin, or some other drug 8 9.3
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Past 12 Mo Sexual Behaviors
Total
No. %
Ever injected illicit drugs
 No 188 83.6
 Yes 37 16.4
Sex while under the influence of drugs/alcohol with last male partner
 No 128 62.8
 Yes 76 37.3
Total 227
May not sum to total due to rounding and missing values.
*Of the 86 participants who used drugs in the 12 months preceding the interview; participants may have used more than one type of drug.
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